Enliven Therapeutics (NASDAQ:ELVN) CFO Benjamin Hohl Sells 6,018 Shares of Stock

Enliven Therapeutics, Inc. (NASDAQ:ELVN) CFO Benjamin Hohl sold 6,018 shares of Enliven Therapeutics stock in a transaction that occurred on Wednesday, June 17th. The stock was sold at an average price of $43.80, for a total transaction of $263,588.40. Following the transaction, the chief financial officer directly owned 51,000 shares in the company, valued at $2,233,800. This trade represents a 10.55% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Enliven Therapeutics Trading Up 1.9%

Shares of ELVN traded up $0.86 during mid-day trading on Monday, reaching $45.96. The company’s stock had a trading volume of 2,517,152 shares, compared to its average volume of 1,260,113. Enliven Therapeutics, Inc. has a 52 week low of $14.78 and a 52 week high of $48.53. The stock has a market cap of $2.80 billion, a PE ratio of -27.52 and a beta of 0.29. The company’s fifty day moving average price is $41.81 and its two-hundred day moving average price is $31.59.

Enliven Therapeutics (NASDAQ:ELVN) last released its earnings results on Thursday, May 7th. The company reported ($0.38) EPS for the quarter, beating the consensus estimate of ($0.44) by $0.06. Research analysts anticipate that Enliven Therapeutics, Inc. will post -1.71 EPS for the current year.

Institutional Trading of Enliven Therapeutics

Several large investors have recently modified their holdings of ELVN. KBC Group NV bought a new stake in shares of Enliven Therapeutics in the 1st quarter worth approximately $38,000. Mirae Asset Global Investments Co. Ltd. lifted its stake in Enliven Therapeutics by 25.9% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,884 shares of the company’s stock worth $44,000 after acquiring an additional 594 shares during the period. BNP Paribas Financial Markets boosted its holdings in Enliven Therapeutics by 33.3% in the second quarter. BNP Paribas Financial Markets now owns 3,722 shares of the company’s stock valued at $75,000 after acquiring an additional 930 shares in the last quarter. Los Angeles Capital Management LLC purchased a new position in Enliven Therapeutics during the 4th quarter valued at $83,000. Finally, Quantbot Technologies LP raised its holdings in Enliven Therapeutics by 47.1% in the 2nd quarter. Quantbot Technologies LP now owns 4,477 shares of the company’s stock worth $90,000 after purchasing an additional 1,434 shares in the last quarter. 95.08% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

A number of equities research analysts have recently weighed in on ELVN shares. The Goldman Sachs Group boosted their target price on Enliven Therapeutics from $41.00 to $59.00 and gave the company a “buy” rating in a research note on Friday, May 8th. Guggenheim assumed coverage on Enliven Therapeutics in a research note on Tuesday, May 12th. They issued a “buy” rating and a $80.00 price target on the stock. Stifel Nicolaus began coverage on Enliven Therapeutics in a research report on Tuesday, June 9th. They issued a “buy” rating and a $60.00 price objective for the company. Weiss Ratings reissued a “sell (d-)” rating on shares of Enliven Therapeutics in a research note on Monday, April 20th. Finally, Wall Street Zen upgraded shares of Enliven Therapeutics from a “sell” rating to a “hold” rating in a report on Monday, May 11th. One equities research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $63.40.

Enliven Therapeutics Company Profile

Enliven Therapeutics is a clinical-stage biotechnology company focused on developing small-molecule therapies that harness induced proximity mechanisms to selectively target and degrade disease-causing proteins in cancer. Leveraging its proprietary Induced Proximity platform, the company designs molecular glues and related modalities to recruit endogenous cellular machinery for targeted protein degradation, with the goal of treating malignancies driven by so-called “undruggable” oncogenic factors.

The company’s pipeline comprises several early-stage programs directed at key oncogenic drivers across hematologic and solid tumor indications.